KNSA
Kiniksa Pharmaceuticals Ltd
NASDAQ: KNSA · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$52.99
-1.60% today
Updated 2026-04-29
Market cap
$4.08B
P/E ratio
58.23
P/S ratio
6.02x
EPS (TTM)
$0.91
Dividend yield
—
52W range
$25 – $54
Volume
0.8M
WallStSmart proprietary scores
51
out of 100
Grade: C
Hold
Investment rating
10.0
Growth
A+8.5
Quality
A6.0
Profitability
B5.7
Valuation
C+4/9
Piotroski F-Score
Moderate
2.7
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$62.50
+17.95%
12-Month target
$23.74
-55.20%
Intrinsic (DCF)
$202.90
Margin of safety
+77.83%
1 Strong Buy7 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Free cash flow $53.26M — positive
+ Revenue growth 65.00% QoQ
+ 77.83% below intrinsic value
+ Debt/equity 0.02x — low leverage
Risks
- P/E 58.23x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $220.18M | $270.26M | $423.24M | $677.56M | $677.56M |
| Net income | $183.36M | $14.08M | $-43.19M | $59.01M | $14.20M |
| EPS | — | — | — | — | $0.91 |
| Free cash flow | $5.70M | $13.17M | $25.41M | $25.41M | $53.26M |
| Profit margin | 83.28% | 5.21% | -10.21% | 8.71% | 8.71% |
Peer comparison
Smart narrative
Kiniksa Pharmaceuticals Ltd trades at $52.99. representing a P/E of 58.23x trailing earnings. Our Smart Value Score of 51/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 2.74, it sits in the grey zone. TTM revenue stands at $677.56M. with profit margins at 8.71%. Our DCF model estimates intrinsic value at $202.90.
Frequently asked questions
What is Kiniksa Pharmaceuticals Ltd's stock price?
Kiniksa Pharmaceuticals Ltd (KNSA) trades at $52.99.
Is Kiniksa Pharmaceuticals Ltd overvalued?
Smart Value Score 51/100 (Grade C, Hold). DCF value $202.90.
What is the price target of Kiniksa Pharmaceuticals Ltd (KNSA)?
The analyst target price is $62.50, representing +17.9% upside from the current price of $52.99.
What is the intrinsic value of Kiniksa Pharmaceuticals Ltd (KNSA)?
Based on our DCF model, intrinsic value is $202.90, a +77.8% margin of safety versus $52.99.
What is Kiniksa Pharmaceuticals Ltd's revenue?
TTM revenue is $677.56M.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
2.74 — grey zone.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio6.02x
ROE11.70%
Beta0.06
50D MA$46.19
200D MA$40.14
Shares out0.05B
Float0.04B
Short ratio—
Avg volume0.8M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—